Relay Therapeutics, Inc. (RLAY) Misses Q2 EPS by 2c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q2 EPS of ($0.41), $0.02 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $733.33 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Roivant Sciences (ROIV) PT Raised to $52 at Jefferies
• NY Fed survey shows rising unemployment fears, mixed financial outlook